- Home
- PLCE vs VTYX Comparison
PLCE vs VTYX Comparison
Compare PLCE & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- VTYX
- Stock Information
- Founded
- PLCE 1969
- VTYX 2018
- Country
- PLCE United States
- VTYX United States
- Employees
- PLCE N/A
- VTYX N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- PLCE Consumer Discretionary
- VTYX Health Care
- Exchange
- PLCE Nasdaq
- VTYX Nasdaq
- Market Cap
- PLCE 170.7M
- VTYX 184.6M
- IPO Year
- PLCE 1997
- VTYX 2021
- Fundamental
- Price
- PLCE $11.25
- VTYX $2.37
- Analyst Decision
- PLCE Hold
- VTYX Buy
- Analyst Count
- PLCE 3
- VTYX 5
- Target Price
- PLCE $11.00
- VTYX $8.40
- AVG Volume (30 Days)
- PLCE 482.3K
- VTYX 2.0M
- Earning Date
- PLCE 12-03-2024
- VTYX 11-07-2024
- Dividend Yield
- PLCE N/A
- VTYX N/A
- EPS Growth
- PLCE N/A
- VTYX N/A
- EPS
- PLCE N/A
- VTYX N/A
- Revenue
- PLCE $1,432,740,000.00
- VTYX N/A
- Revenue This Year
- PLCE N/A
- VTYX N/A
- Revenue Next Year
- PLCE N/A
- VTYX N/A
- P/E Ratio
- PLCE N/A
- VTYX N/A
- Revenue Growth
- PLCE N/A
- VTYX N/A
- 52 Week Low
- PLCE $4.77
- VTYX $1.67
- 52 Week High
- PLCE $38.03
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- PLCE 40.06
- VTYX 49.41
- Support Level
- PLCE $10.51
- VTYX $2.23
- Resistance Level
- PLCE $15.20
- VTYX $3.39
- Average True Range (ATR)
- PLCE 1.46
- VTYX 0.28
- MACD
- PLCE -0.39
- VTYX -0.04
- Stochastic Oscillator
- PLCE 11.80
- VTYX 12.07
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.